SB-633825 is a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), primarily used in research settings to study its effects on the central nervous system. It modulates cAMP signaling in brain regions like the striatum and is investigated for its potential role in psychiatric disorders, particularly schizophrenia, and neurological conditions such as Parkinson's disease. Researchers utilize it to explore PDE10A's involvement in dopamine signaling and medium spiny neuron function. It is employed in preclinical studies to assess efficacy, safety, and interactions with neurotransmitter systems, aiding the development of novel therapeutics for CNS disorders.